Science Corp has closed a massive $230 million Series C funding round, pushing its post-money valuation to $1.5 billion.
The round was led by Lightspeed Venture Partners and Khosla Ventures, with participation from Y Combinator, Quiet Capital, and IQT, bringing total funding to nearly $490 million.
From Neuralink Co-Founder to BCI Trailblazer
Founded by Max Hodak, former president of Neuralink, Science Corp is racing to become the first brain-computer interface company to commercialize its technology.
In 2024, the company acquired the PRIMA assets from Pixium Vision, refining the retinal implant originally developed through European trials.
PRIMA, a chip smaller than a grain of rice, pairs with camera-equipped glasses to restore functional vision for patients with advanced macular degeneration.
Groundbreaking Clinical Results
The device has been implanted in 47 patients across Europe and the U.S., with 80% demonstrating meaningful improvements in visual acuity, including the ability to read letters, numbers, and words.
Hodak claims this marks the first time fluent reading has been definitively restored in blind patients.
The company recently graced the cover of Time magazine, highlighting its potential to transform lives.
Regulatory Milestones and Global Launch
Science Corp has submitted for CE mark approval in the EU, anticipating mid-2026 clearance and an initial launch in Germany.
Ongoing FDA discussions aim to bring the technology to U.S. patients soon after, while trials expand to Stargardt disease and retinitis pigmentosa.
With 150 employees and new capital, the firm will accelerate PRIMA commercialization alongside biohybrid neural interfaces and organ preservation tech.
This funding positions Science Corp ahead of rivals like Neuralink, promising profound impacts on vision loss treatments and the broader BCI market.
Maria Lourdes
